The abstract is read at the publisher; the summary is JClub's.
In the US, 5% to 6% of pregnant patients receive SSRI therapy for major depressive disorder, which affects about 12% and requires careful perinatal risk–benefit decisions.
- Why it matters: Maternal psychiatric illness is a leading contributor to maternal morbidity and mortality, and untreated or undertreated MDD can harm fetal and infant outcomes, creating a two-generation public health stakes.
- What they did: The field reviews evidence on SSRI use in pregnancy, emphasizing how observational confounding by underlying indication can be disentangled to assess drug-specific safety in perinatal MDD.
- The result: Accumulated evidence suggests SSRI carry little or no risk for serious adverse outcomes, supporting structured decision-making that balances risks of untreated illness against SSRI exposure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.